Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes - Concepedia

Concepedia

Publication | Open Access

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

DOI Full Paper Access

436

Citations

35

References

2021

Year

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero, David P. Steensma, Gail J. Roboz, Mikkael A. Sekeres, Thomas Cluzeau, Kendra Sweet, Amy F. McLemore, Kathy L. McGraw,

Journal of Clinical Oncology

Abstract

Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with <i>TP53</i>-mutant MDS and oligoblastic AML.

References

	Year	Citations

Page 1